RxDoctor Payments Data

Michael Degaetano, DO

Nephrology · San Antonio, TXNPI 1881660454

Payments from drug & device makers

$13,650in general payments, 2019–2025

Across 757 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$2K
  • Daiichi Sankyo Inc.$1K
  • Fresenius USA Marketing, Inc.$1K
  • OPKO Pharmaceuticals, LLC$744
  • Akebia Therapeutics Inc$707
  • plus $6K from 30 others

What the payments were for

  • Food & beverage$13,596100%
  • Education$540%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,650 in reported general payments places this provider in the 80th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$377,446
Medicare patients
514
Services billed
4,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol323$303,473
VelphoroSucroferric Oxyhydroxide87$180,703
AuryxiaFerric Citrate56$103,910
MounjaroTirzepatide74$82,492
RayaldeeCalcifediol61$74,667
XphozahTenapanor Hcl20$63,244
VeltassaPatiromer Calcium Sorbitex48$62,834
EntrestoSacubitril/Valsartan41$57,755
JardianceEmpagliflozin65$55,928
KerendiaFinerenone40$45,631
LokelmaSodium Zirconium Cyclosilicate50$36,107
LinzessLinaclotide23$26,310
OzempicSemaglutide24$25,046
DapagliflozinDapagliflozin Propanediol20$11,605
Cinacalcet Hcl37$9,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$2,431$339,580373 claims
Fresenius USA Marketing, Inc.Velphoro$1,013$180,70387 claims
Akebia Therapeutics IncAuryxia$707$103,91056 claims
Lilly USA, LLCMounjaro$75$82,49274 claims
OPKO Pharmaceuticals, LLCRayaldee$744$74,66761 claims
NovartisEntresto$390$57,75541 claims
Boehringer IngelheimJardiance$168$55,92865 claims
BayerKerendia$540$45,63140 claims
AbbVieLinzess$166$26,31023 claims
Novo NordiskOzempic$102$25,04624 claims
Arbor Pharmaceuticals, Inc.Edarbi$143$5,20016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,070 nephrology providers in Texas.

Other nephrology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →